Thermally Gelling Mitomycin Composition for Bladder Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for low-grade intermediate-risk non-muscle invasive bladder cancer (LG IR NMIBC) are inadequate, leading to high recurrence rates and the need for repetitive surgeries, which pose risks to patients.
Innovation Solution
Administration of a thermally gelling pharmaceutical composition comprising a reverse thermal gelation agent, cellulose derivatives, and mitomycin to the bladder once weekly for six weeks, reducing the need for repetitive surgeries.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If TURBT monotherapy is used to treat low-grade intermediate-risk non-muscle invasive bladder cancer, then the treatment procedure is simple and widely available, but the recurrence rate is high and patients require repetitive surgeries
Solution Approach 1:
The patent combines mitomycin (a chemotherapy agent) with a reverse thermal gelation system to create a composite pharmaceutical composition. The gel matrix (composed of poloxamer and hydroxypropylmethylcellulose) serves as a delivery vehicle that releases mitomycin sustainably, enhancing the therapeutic effect while maintaining a relatively simple administration procedure through catheter-based instillation
Solution Approach 2:
The patent utilizes temperature-dependent phase transition of the gel composition. The formulation is administered as a liquid at low temperature (stored at 2-8°C) and transforms into a gel at body temperature (37°C) within the bladder. This parameter change enables extended dwell time and sustained drug release, improving treatment efficacy without requiring complex delivery devices
2Reliability
If repetitive TURBT surgeries are performed to manage recurrent bladder cancer, then tumor recurrence can be controlled, but patient risk increases due to repeated anesthesia and surgical intervention
Solution Approach 1:
The patent applies adjuvant intravesical therapy with mitomycin gel immediately following TURBT surgery while the bladder is still accessible and the tumor bed is fresh. This preliminary action targets residual cancer cells before they can regrow, reducing recurrence risk and potentially eliminating the need for future repeat surgeries and their associated risks
Solution Approach 2:
The reverse thermal gel acts as an intermediary delivery system that provides sustained release of mitomycin directly at the tumor site. This localized, prolonged exposure to the chemotherapy agent enhances cancer cell destruction while minimizing systemic side effects and reducing the need for repeated surgical interventions
3Reliability
If aqueous mitomycin is administered for extended dwell time, then treatment efficacy improves, but urine production dilutes the medication and reduces therapeutic effect
Solution Approach 1:
The patent exploits the phase transition of the gel formulation from liquid to gel state at body temperature. This phase change occurs spontaneously upon instillation into the bladder, creating a semi-solid matrix that resists dilution by urine production. The gel structure maintains high local concentration of mitomycin throughout the dwell period, ensuring sustained therapeutic effect
Solution Approach 2:
The gel matrix serves as an intermediary that physically separates the mitomycin from the diluting effect of urine. By embedding the drug in the gel network, the formulation maintains stable drug concentration despite continuous urine flow, allowing extended dwell times without significant dilution
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly reduces the risk of bladder tumor recurrence, progression, or death, and increases the probability of disease-free survival and maintaining complete response for at least 15 months compared to TURBT monotherapy.
Implementation Method 1
a thermally gelling pharmaceutical composition comprising a reverse thermal gelation agent
Data Source
AI summary
A method of reducing risk of bladder tumor recurrence, progression or death, or a method of increasing probability of disease-free survival at 15 months post-treatment, or a method of increasing probability of maintaining an achieved complete response for at least 15 months post-treatment comprises administering to a patient in need thereof a thermally gelling pharmaceutical composition once weekly for six weeks, the patient having low-grade intermediate-risk non-muscle invasive bladder cancer, and the thermally gelling pharmaceutical composition comprising a reverse thermal gelation agent, a polymer, and mitomycin. The risk is reduced or the probability is increased in comparison to the risk or probability expected if the patient were instead to receive TURBT monotherapy as treatment.